Fore expects its employees and leadership to uphold ethical and compliant behavior in their dealings with colleagues, the public, business and scientific partners, patients and patients’ families.
Mr. Sacher has 30 years of experience in biotechnology and investment banking. As a managing director and head of life sciences investment banking at several firms, he executed more than 130 transactions, including more than $5 billion in financings.
Mr. Byrnes has over 20 years of biotechnology experience across development stages and indications, including oncology. He was chief financial officer of eFFECTOR Therapeutics and senior vice president of finance at Principia Biopharma, Inc. (PRNB).
Plixorafenib, is a novel investigational, next-generation BRAF inhibitor designed to inhibit a wide randge of BRAF gene alterantions in cancer cells while overcoming limitiations of earlier-generation BRAF inhibitors.
